The introduction of 750mcg teriparatide solution in Australia has experienced modest sales . Currently, it’s largely prescribed for patients with severe osteoporosis where other treatments have not been effective. Obtaining this higher-dose formulation presents as challenging due to healthcare approval requirements and limited hospital stock . De